APTUS PHARMA H1 : STANDALONE NET PROFIT UP 191% AT ₹5.07 CR (YOY). STRONG (ON 1ST LOOK)

Revenue up 166% at ₹48.92 Cr (YOY); EBITDA at ₹7.68 Cr with margin ~15.7%. PAT up 191% at ₹5.07 Cr (YOY); EPS at ₹2.96 v ₹1.37 (YOY). Targets 46% geographic coverage across India by March 2027. Proposed preferential issue of 16.03 lakh shares at ₹280, aggregating ₹44.88 Cr; no shares allotted yet.

Aptus Pharma Ltd

Open attachment

← Back to feed